OSMT लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (19 Jan 2022 @ 10:30):

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary...

Stats
आज की मात्रा	296 322
औसत मात्रा	594 359
बाजार मूल्य	110.18M
EPS	$-0.280 ( 2021-11-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.694
ATR14	$0.0990 (8.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-01-24	Klein Christopher	Sell	9 605	Ordinary Shares
2020-05-20	Cowan Gregory L	Buy	38 716	Ordinary Shares
2020-05-21	Cowan Gregory L	Sell	11 112	Ordinary Shares
2020-01-28	Schaub James	Sell	9 197	Ordinary Shares
2019-01-24	Weiss Fred G	Buy	34 403	Ordinary Shares

INSIDER POWER
0.00
Last 6 transactions
Buy: 177 968 \| Sell: 29 914

मात्रा सहसंबंध

लंबा: -0.10 (neutral)

छोटा: 0.02 (neutral)

Signal:(45.447) Neutral

Osmotica Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
GOODM	0.927
OPK	0.842
CHKEL	0.827
SY	0.81
MHLD	0.804

10 सबसे अधिक नकारात्मक सहसंबंध
CFBK	-0.899
DOX	-0.871
ARDX	-0.87
GLBZ	-0.865
CERC	-0.853
FATP	-0.852
IMTX	-0.852
PBPB	-0.848
CRVS	-0.845
ECOR	-0.843

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Osmotica Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

-0.70
( moderate negative )

-0.85
( strong negative )

0.26
( neutral )

-0.52
( weak negative )

-0.60
( weak negative )

0.62
( weak )

Osmotica Pharmaceuticals वित्तीय

Annual	2022
राजस्व:	$49.72M
सकल लाभ:	$40.27M (80.98 %)
EPS:	$-0.580

FY	2022
राजस्व:	$49.72M
सकल लाभ:	$40.27M (80.98 %)
EPS:	$-0.580

FY	2020
राजस्व:	$177.88M
सकल लाभ:	$103.40M (58.13 %)
EPS:	$-1.520

FY	2019
राजस्व:	$240.03M
सकल लाभ:	$128.40M (53.49 %)
EPS:	$-5.17

Financial Reports:

No articles found.

Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.